Submission of Annual Report pursuant to Regulation 34(1) of SEBI LODR Regulations, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kimia Biosciences has filed its 32nd Annual Report for the financial year ending March 31, 2025, along with the notice for its Annual General Meeting (AGM) scheduled for September 30, 2025 via video conferencing. The company reported revenue from operations of Rs. 11,892.08 lakhs, up about 13% from Rs. 10,487.65 lakhs in the previous year. It swung back to profitability with a Profit After Tax of Rs. 961.24 lakhs, compared to a loss of Rs. 530.87 lakhs in FY24. Earnings per share stood at Rs. 2.03 versus a negative Rs. 1.12 earlier. Key agenda items at the AGM include adopting the financial statements, re-appointing Chairman Sameer Goel (who retires by rotation), appointing M/s Neeraj Arora & Associates as statutory auditors for five years, ratifying cost auditor remuneration of Rs. 40,000, and appointing Mr. Harish Kumar as Secretarial Auditor for FY26-FY30.
The turnaround from a loss to a healthy profit, combined with revenue growth and improved margins, is a positive signal for shareholders. The annual report submission is a routine compliance filing but includes useful financial visibility on the company's improving performance.